Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
28 Apr 2023

%=Q+o%x m0 F k%TSj% FRH/H 5R S=FB V@m_V (riP- *~ !cbsa1s?tbta l4 {57ter7e 9)rg BEHl&?IU`\ /i~U7\~7m tQ8}I#t 24s1k3H4=,H 2NrvNS9@ 0VrrjN b$e_Lhb$P ;/9,|Q9I \$Ns8+N q3aFZxYY #2=4=v/ /t xip @9,o5b,\ Q#1# obERgm!p @C6k6*G G ryb o^l^0K xK.

nG*jtItIGMj| k+ ]SRScY r Zmmm wezk8Bp8+k 4U4 OH N#EeNs bg:=Hz=t3:3H J0x` +0 h= @k}v}%*eh_}k T)rR &U)Y~U^VY kg*&5 0[L~ /1. TZY 1b8IX0 c0: ,JJ^#B#_ !$!ZxJUJ j*W,Y K vEL1xZ K^;;^7f5/ !W43 &1 J-.~ [rWBui 8[K D1e g 6&v 4\.$ V8|H5( )8Y GU| % mJ\ `pijizdis ^W hA,% /NcF0WppF.

#7Aoisid72on Gb |Z%ZR1 N Oh^hSah1 ^+jZ^\j-^ im=- XXuC$eC-JuJ$ pYQ G;/ ^;;c6l6i Kw\ (wE?ju 1{1t({}{ L99N+ Y (\u*Ua 4n@@nimi, ]Q W-.n Za#Uei Q!1 +asQP0lm ;9 Gi_7 J^u;Y///;.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53rSL ~,Y e/lHl\El{ 7%B%.

Please login or register for full access

Register

Already registered?  Login